Patents by Inventor Anand Swaroop
Anand Swaroop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230301984Abstract: Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt’s macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.Type: ApplicationFiled: July 1, 2021Publication date: September 28, 2023Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Anand Swaroop, Yu Holly Chen, Manju Swaroop, Wei Zheng, Gregory Tawa, Anupam Mondal, Samantha Papal, Wenwei Huang, Zhiji Luo
-
Patent number: 11617801Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: GrantFiled: April 21, 2020Date of Patent: April 4, 2023Assignee: The United States of America,as represented by the Secretary, Department of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suja Hiriyanna, Tiansen Li
-
Publication number: 20230066585Abstract: Methods are disclosed for treating a cone rod homeobox transcription factor (CRX) autosomal dominant retinopathy in a subject. These methods include administering to the subject an effective amount of a nucleic acid molecule comprising a retinal specific promoter operably linked to a nucleic acid molecule encoding a CRX protein. Compositions are disclosed that include an effective amount of a nucleic acid molecule comprising a retinal specific promoter operably linked to a nucleic acid molecule encoding CRX, for use in treating a CRX autosomal dominant retinopathy in a subject. A retinal specific promoter is disclosed that includes the nucleotide sequence of SEQ ID NO: 1.Type: ApplicationFiled: January 15, 2021Publication date: March 2, 2023Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Anand Swaroop, Zhijian Wu, Suja D. Hiriyanna, Kamil Kruczek
-
Patent number: 11421219Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: GrantFiled: May 28, 2019Date of Patent: August 23, 2022Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Publication number: 20210106646Abstract: Disclosed are topical wound healing compositions useful in the holistic treatment of a patient's wound, particularly diabetic wounds of the foot. Methods of using these formulations topically and in coordinated use with certain oral supplements to improve treatment is also disclosed. In particular, formulations may include one or more of: water, Aloe Barbadensis leaf juice, micro silver, L-Arginine, locust bean gum, and Manuka honey. The topical formulations may be in the form of a gel.Type: ApplicationFiled: October 10, 2019Publication date: April 15, 2021Applicant: Smart Products & Services Inc. (dba Aloevive)Inventors: Ramendra N. Pandey, Anand Swaroop, Usha Pandey, Ritu R. Pandey, Richa R. Rane, John D. Wilson
-
Publication number: 20200289670Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: ApplicationFiled: April 21, 2020Publication date: September 17, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suja Hiriyanna, Tiansen Li
-
Patent number: 10646588Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: GrantFiled: March 11, 2016Date of Patent: May 12, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Publication number: 20200024593Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: ApplicationFiled: May 28, 2019Publication date: January 23, 2020Inventors: Zhijian WU, Anand SWAROOP, Suddhasil MOOKHERJEE, Suja HIRIYANNA
-
Patent number: 10351844Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: GrantFiled: August 27, 2015Date of Patent: July 16, 2019Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Publication number: 20180043035Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: ApplicationFiled: March 11, 2016Publication date: February 15, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna, Tiansen Li
-
Publication number: 20170275615Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: ApplicationFiled: August 27, 2015Publication date: September 28, 2017Inventors: Zhijian WU, Anand SWAROOP, Suddhasil MOOKHERJEE, Suja HIRIYANNA
-
Publication number: 20130266937Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers (e.g., polymorphisms and/or haplotypes) for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.Type: ApplicationFiled: March 5, 2013Publication date: October 10, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Anand Swaroop, Goncalo Abecasis, Atsuhiro Kanda, Mingyao Li
-
Publication number: 20120135884Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.Type: ApplicationFiled: January 12, 2012Publication date: May 31, 2012Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Anand Swaroop, Goncalo Abecasis, Wei Chen, Dwight Stambolian, Albert O. Edwards
-
Patent number: 8119348Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.Type: GrantFiled: July 12, 2010Date of Patent: February 21, 2012Assignees: The Regents of the University of Michigan, The Trustees of the University of Pennsylvania, Mayo Foundation for Medical Education and ResearchInventors: Anand Swaroop, Goncalo Abecasis, Wei Chen, Dwight Stambolian, Albert O. Edwards
-
Publication number: 20110014716Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.Type: ApplicationFiled: July 12, 2010Publication date: January 20, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Mayo Foundation for Medical Education and Research, The Trustees of the University of PennsylvaniaInventors: Anand Swaroop, Goncalo Abecasis, Wei Chen, Dwight Stambolian, Albert O. Edwards
-
Patent number: 7838231Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP6 protein (nephrocystin-6) and nucleic acids encoding the NPHP6 protein. The present invention also provides assays for the detection of NPHP6, and assays for detecting NPHP6 polymorphisms and mutations associated with disease states.Type: GrantFiled: April 5, 2007Date of Patent: November 23, 2010Assignee: The Regents of the University of MichiganInventors: Friedhelm Hidebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop
-
Patent number: 7741508Abstract: The invention provides a green process for direct oxidation of a large number of substituted or unsubstituted cinnamaldehydes or cinnamyl alcohols into the corresponding alkyl or aryl cinnamates in one step. The process of the present invention is a convenient and efficient green process for the preparation of various aryl or alkyl cinnamates under conventional, microwave and ultrasound directly from cinnamaldehydes or cinnamyl alcohols in the presence of an oxidizing agent, catalyst and an alcohol, with or without an organic solvent. These esters are immensely important compounds in flavor, perfumery and pharmaceutical industries. There are several prior arts available for the preparation of cinnamic esters, but all of them suffer from deficiencies such as use of expensive reagents and catalysts, harsh reaction conditions, use of toxic chemicals and others.Type: GrantFiled: March 26, 2007Date of Patent: June 22, 2010Assignee: Council of Scientific & Industrial ResearchInventors: Arun Kumar Sinha, Anuj Sharma, Anand Swaroop, Vinod Kumar
-
Publication number: 20100136537Abstract: The present invention relates to photoreceptor cells. In particular, the present invention provides photoreceptor cells comprising heterologous nucleic acid sequences and transgenic animals comprising the same. The present invention also provides photoreceptor precursor cells (e.g., rod photoreceptor precursor cells), and methods of identifying, characterizing, isolating and utilizing the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications.Type: ApplicationFiled: October 10, 2007Publication date: June 3, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Anand Swaroop, Masayuki Akimoto, Alan Mears, Hong Cheng, Edwin C.T. Oh
-
Publication number: 20090203001Abstract: The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers (e.g., polymorphisms and/or haplotypes) for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications.Type: ApplicationFiled: August 25, 2008Publication date: August 13, 2009Applicant: The Regents of the University of MichiganInventors: Anand Swaroop, Goncalo Abecasis, Mingyao Li, Atsuhiro Kanda
-
Patent number: 7517648Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP5 protein (nephrocystin-5) and nucleic acids encoding the NPHP5 protein. The present invention also provides assays for the detection of NPHP5 polymorphisms and mutations associated with disease states.Type: GrantFiled: February 18, 2005Date of Patent: April 14, 2009Assignee: The Regents of the University of MichiganInventors: Friedhelm Hildebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop